RxDoctor Payments Data

Salvatore Bavuso, MD

Family Medicine · Lively, VANPI 1407835937

Payments from drug & device makers

$1,163in general payments, 2019–2025

Across 68 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$386
  • Abbott$152
  • Novo Nordisk$109
  • Supernus Pharmaceuticals, Inc.$92
  • GSK$56
  • Johnson & Johnson$52
  • plus $317 from 11 others

What the payments were for

  • Food & beverage$1,163100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,163 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$9,105
Medicare patients
82
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin272$215,979
EliquisApixaban180$203,482
OzempicSemaglutide178$198,662
FarxigaDapagliflozin Propanediol174$152,465
MounjaroTirzepatide53$78,849
TrulicityDulaglutide70$70,778
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$43,185
XareltoRivaroxaban34$40,056
EntrestoSacubitril/Valsartan21$25,939
Xultophy 100-3.6Insulin Degludec/Liraglutide21$25,626
WegovySemaglutide15$20,577
Soliqua 100-33Insulin Glargine/Lixisenatide20$18,882
Breo ElliptaFluticasone/Vilanterol17$13,652
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$13,221
MyrbetriqMirabegron12$12,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Wegovy$109$244,865214 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr$37$233,139299 claims
PfizerEliquis$48$203,482180 claims
AstraZenecaFarxiga, Symbicort$386$162,226196 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$56$70,05871 claims
Johnson & JohnsonXarelto$52$40,05634 claims
NovartisEntresto$18$25,93921 claims
Astellas Pharma US IncMyrbetriq$18$12,61212 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$15$5,96812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Lively

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →